UBS Group
NMTR

UBS Group’s 9 Meters Biopharma NMTR Stock Holding History

UBS Group’s Portfolio NMTR Stock Details NMTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,340
Closed -$6.03K – 10208
2023
Q1 		$6.03K Sell
4,340
-7,989
-65% -$15.1K ﹤0.01% 7967
2022
Q4 		$15.5K Buy
12,329
+6,584
+115% +$15K ﹤0.01% 7968
2022
Q3 		$25K Sell
5,745
-1
-0% -$5 ﹤0.01% 7124
2022
Q2 		$30K Buy
5,746
+4,314
+301% +$40.6K ﹤0.01% 6408
2022
Q1 		$17K Sell
1,432
-4,456
-76% -$60.8K ﹤0.01% 7699
2021
Q4 		$116K Buy
5,888
+2,733
+87% +$61.1K ﹤0.01% 6176
2021
Q3 		$82K Buy
3,155
+240
+8% +$5.66K ﹤0.01% 5969
2021
Q2 		$64K Buy
2,915
+1,139
+64% +$28K ﹤0.01% 6216
2021
Q1 		$42K Sell
1,776
-1,978
-53% -$60.8K ﹤0.01% 6733
2020
Q4 		$64K Buy
3,754
+3,694
+6,157% +$61.6K ﹤0.01% 5973
2020
Q3 		$1K Buy
+60
New +$727 ﹤0.01% 7873
2020
Q2 		– Sell
-85
Closed -$1K – 8497
2020
Q1 		$1K Sell
85
-425
-83% -$5.33K ﹤0.01% 7841
2019
Q4 		$6K Buy
+510
New +$8.49K ﹤0.01% 7547
2019
Q3 		– Sell
-3
Closed – – 8363
2019
Q2 		$0 Buy
+3
New +$90 ﹤0.01% 8259
2019
Q1 		– Sell
-690
Closed -$32K – 8319
2018
Q4 		$32K Buy
690
+640
+1,280% +$47.4K ﹤0.01% 6449
2018
Q3 		$7K Sell
50
-331
-87% -$56.9K ﹤0.01% 7356
2018
Q2 		$179K Buy
+381
New +$140K ﹤0.01% 5035
2018
Q1 		– Sell
-68
Closed -$8K – 8275
2017
Q4 		$8K Buy
68
+12
+21% +$1.54K ﹤0.01% 7175
2017
Q3 		$8K Buy
56
+10
+22% +$1.56K ﹤0.01% 7016
2017
Q2 		$4K Buy
+46
New +$6.42K ﹤0.01% 7235
2017
Q1 		– Sell
-10
Closed -$3K – 8091
2016
Q4 		$3K Buy
+10
New +$2.9K ﹤0.01% 7444

Other funds holding NMTR

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ODFS
O'Donnell Financial Services San Rafael, California $290M AUM 15.6% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
CIBC Asset Management
CIBC Asset Management Toronto, Ontario, Canada $40.9B AUM 35.96% 1-Year Est. Return

UBS Group's NMTR Position: Q2 2023 in Review

UBS Group sold out of 9 Meters Biopharma (NMTR) in Q2 2023, closing a stake of 4,340 shares — an estimated $6.03K sold.

UBS Group first reported a position in NMTR in Q4 2016 and held it in 21 quarters. The position peaked at $179K in Q2 2018. 34 funds tracked by Wall St. Rank hold NMTR as of Q2 2023.

  • UBS Group reported no remaining 9 Meters Biopharma position as of Q2 2023 after selling out during the quarter.
  • UBS Group sold 4,340 9 Meters Biopharma shares in Q2 2023, an estimated $6.03K.
  • UBS Group first reported a position in 9 Meters Biopharma in Q4 2016 and held it in 21 quarters.
  • UBS Group's 9 Meters Biopharma position peaked at $179K in Q2 2018.
  • 34 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.